1. Weidmann, M.D., Ofori, K. & Rai, A.J. Laboratory Biomarkers in the Management of Patients With COVID-19. Am J Clin Pathol 155, 333-342 (2021).
2. Johns Hopkins University and Medicine (2021). Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) (2021).
3. Pierron, D. et al. Smell and taste changes are early indicators of the COVID-19 pandemic and political decision effectiveness. Nat Commun 11, 5152 (2020).
4. Du, R.H. et al. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. Ann Am Thorac Soc 17, 839-846 (2020).
5. Younis, N.K., Zareef, R.O., Maktabi, M.A.N. & Mahfouz, R. The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. Genet Test Mol Biomarkers 25, 85-101 (2021).
6. Amdal, C.D. et al. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. Qual Life Res (2021).
7. Williamson, E.J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430-436 (2020).
8. Velavan, T.P. et al. Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine 72, 103629 (2021).
9. Venkatakrishnan, A.J. et al. Mapping each pre-existing condition's association to short-term and long-term COVID-19 complications. NPJ Digit Med 4, 117 (2021).
10. Moghadas, S.M. et al. The impact of vaccination on COVID-19 outbreaks in the United States. Clin Infect Dis (2021).
11. Barber, T.M. COVID-19 and diabetes mellitus: implications for prognosis and clinical management. Expert Rev Endocrinol Metab 15, 227-236 (2020).
12. Al-Sabah, S., Al-Haddad, M., Al-Youha, S., Jamal, M. & Almazeedi, S. COVID-19: Impact of obesity and diabetes on disease severity. Clin Obes 10, e12414 (2020).
13. Halvatsiotis, P. et al. Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. Diabetes Res Clin Pract 166, 108331 (2020).
14. Aiyegbusi, O.L. et al. Symptoms, complications and management of long COVID: a review. J R Soc Med 114, 428-442 (2021).
15. Elhiny, R., Al-Jumaili, A.A. & Yawuz, M.J. An overview of post-COVID-19 complications. Int J Clin Pract 75, e14614 (2021).
16. Samprathi, M. & Jayashree, M. Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr 8, 607647 (2020).
17. Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A. & Ozben, T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 57, 389-399 (2020).
18. Topp, G. et al. Biomarkers Predictive of Extubation and Survival of COVID-19 Patients. Cureus 13, e15462 (2021).
19. Malik, P. et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med 26, 107-108 (2021).
20. Narvel, H., Sayed, A., Narvel, N., Yakkali, S. & Katchi, T. Do Certain Biomarkers Predict Adverse Outcomes in Coronavirus Disease 2019? J Clin Med Res 13, 195-203 (2021).
21. Li, M.Y., Li, L., Zhang, Y. & Wang, X.S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9, 45 (2020).
22. Song, J. et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol 92, 2556-2566 (2020).
23. Tumpara, S. et al. Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by alpha-1 Antitrypsin. Int J Mol Sci 22(2021).
24. Mansouri, K. et al. Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational. Biomed Pharmacother 131, 110694 (2020).
25. Codo, A.C. et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1alpha/Glycolysis-Dependent Axis. Cell Metab 32, 498-499 (2020).
26. Krishnan, S. et al. Metabolic perturbation associated with COVID-19 disease severity and SARS-CoV-2 replication. Mol Cell Proteomics, 100159 (2021).
27. Ajaz, S. et al. Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. Am J Physiol Cell Physiol 320, C57-C65 (2021).
28. Moolamalla, S.T.R., Balasubramanian, R., Chauhan, R., Priyakumar, U.D. & Vinod, P.K. Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems biology approach. Microb Pathog 158, 105114 (2021).
29. Gibellini, L. et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol Med 12, e13001 (2020).
30. Singh, K. et al. Network Analysis and Transcriptome Profiling Identify Autophagic and Mitochondrial Dysfunctions in SARS-CoV-2 Infection. bioRxiv (2020).
31. Richard, J.P. Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21, 549-53 (1993).
32. Thornalley, P.J. The glyoxalase system in health and disease. Mol Aspects Med 14, 287-371 (1993).
33. Sousa Silva, M., Gomes, R.A., Ferreira, A.E., Ponces Freire, A. & Cordeiro, C. The glyoxalase pathway: the first hundred years... and beyond. Biochem J 453, 1-15 (2013).
34. Antognelli, C., Palumbo, I., Aristei, C. & Talesa, V.N. Glyoxalase I inhibition induces apoptosis in irradiated MCF-7 cells via a novel mechanism involving Hsp27, p53 and NF-kappaB. Br J Cancer 111, 395-406 (2014).
35. Ranganathan, S., Ciaccio, P.J., Walsh, E.S. & Tew, K.D. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 240, 149-55 (1999).
36. Schalkwijk, C.G. & Stehouwer, C.D.A. Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases. Physiol Rev 100, 407-461 (2020).
37. Schofield, C.J. & Ratcliffe, P.J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5, 343-54 (2004).
38. Alomar, F. et al. Smooth muscle-generated methylglyoxal impairs endothelial cell-mediated vasodilatation of cerebral microvessels in type 1 diabetic rats. Br J Pharmacol 173, 3307-3326 (2016).
39. Alomar, F.A. et al. Adeno-Associated Viral Transfer of Glyoxalase-1 Blunts Carbonyl and Oxidative Stresses in Hearts of Type 1 Diabetic Rats. Antioxidants (Basel) 9(2020).
40. Arriagada-Petersen, C. et al. Effect of advanced glycation end products on platelet activation and aggregation: a comparative study of the role of glyoxal and methylglyoxal. Platelets 32, 507-515 (2021).
41. Gawlowski, T., Stratmann, B., Stirban, A.O., Negrean, M. & Tschoepe, D. AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation. Thromb Res 121, 117-26 (2007).
42. Lin, C.C. et al. Methylglyoxal activates NF-kappaB nuclear translocation and induces COX-2 expression via a p38-dependent pathway in synovial cells. Life Sci 149, 25-33 (2016).
43. Masih, A. et al. Discovery of novel pyrazole derivatives as a potent anti-inflammatory agent in RAW264.7 cells via inhibition of NF-kB for possible benefit against SARS-CoV-2. J Biochem Mol Toxicol 35, e22656 (2021).
44. Oliveira, E. et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS One 16, e0249038 (2021).
45. Salmi, M. & Jalkanen, S. VAP-1: an adhesin and an enzyme. Trends Immunol 22, 211-6 (2001).
46. Hishida, E. et al. Crucial Role of NLRP3 Inflammasome in the Development of Peritoneal Dialysis-related Peritoneal Fibrosis. Sci Rep 9, 10363 (2019).
47. Black, S., Kushner, I. & Samols, D. C-reactive Protein. J Biol Chem 279, 48487-90 (2004).
48. Horowitz, R.I., Freeman, P.R. & Bruzzese, J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respir Med Case Rep 30, 101063 (2020).
49. Carlberg, I. & Mannervik, B. Glutathione reductase. Methods Enzymol 113, 484-90 (1985).
50. Seelig, G.F. & Meister, A. Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. Methods Enzymol 113, 379-90 (1985).
51. Su, C.M., Wang, L. & Yoo, D. Activation of NF-kappaB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. Sci Rep 11, 13464 (2021).
52. Wang, G.L., Jiang, B.H., Rue, E.A. & Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92, 5510-4 (1995).
53. Wang, G.L. & Semenza, G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270, 1230-7 (1995).